Hsbc Holdings PLC purchased a new stake in shares of Celcuity, Inc. (NASDAQ:CELC – Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 10,636 shares of the company’s stock, valued at approximately $1,058,000.
Several other large investors have also made changes to their positions in CELC. EverSource Wealth Advisors LLC increased its holdings in Celcuity by 1,329.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after buying an additional 319 shares during the last quarter. US Bancorp DE lifted its stake in Celcuity by 25.4% in the third quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after acquiring an additional 143 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in Celcuity by 78.9% in the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after acquiring an additional 1,167 shares during the last quarter. Meeder Asset Management Inc. bought a new stake in Celcuity in the fourth quarter worth approximately $42,000. Finally, Ogorek Anthony Joseph NY ADV grew its position in Celcuity by 19.7% in the fourth quarter. Ogorek Anthony Joseph NY ADV now owns 662 shares of the company’s stock worth $66,000 after acquiring an additional 109 shares in the last quarter. Institutional investors own 63.33% of the company’s stock.
Insider Activity at Celcuity
In other Celcuity news, Director David Dalvey sold 25,000 shares of Celcuity stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.68, for a total value of $3,517,000.00. Following the transaction, the director directly owned 65,000 shares of the company’s stock, valued at $9,144,200. The trade was a 27.78% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.46, for a total value of $1,264,140.00. Following the transaction, the director owned 6,760 shares of the company’s stock, valued at approximately $949,509.60. This trade represents a 57.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.33% of the stock is owned by corporate insiders.
Wall Street Analysts Forecast Growth
Get Our Latest Report on Celcuity
Celcuity Stock Down 3.5%
Celcuity stock opened at $103.79 on Tuesday. The firm has a market cap of $5.06 billion, a price-to-earnings ratio of -26.61 and a beta of 0.16. The company has a debt-to-equity ratio of 6.04, a current ratio of 12.31 and a quick ratio of 12.31. Celcuity, Inc. has a fifty-two week low of $13.36 and a fifty-two week high of $151.02. The firm has a fifty day moving average price of $111.44 and a two-hundred day moving average price of $111.07.
Celcuity (NASDAQ:CELC – Get Free Report) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.10. As a group, analysts forecast that Celcuity, Inc. will post -3.69 earnings per share for the current year.
About Celcuity
Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.
Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.
See Also
- Five stocks we like better than Celcuity
- The SK Hynix IPO and 2027’s AI Memory Squeeze
- Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
- Why Welltower’s Growth Story Might Outrun Its Rich Valuation
- One Short- and One Long-Term ETF for Quantum Computing Bulls
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.
